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sinus node dysfunction. Second, total power (i.e., a quantitative
measure of heart rate variability) was similar both in patients with
early recurrence and in subjects who maintained sinus rhythm.
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Over-AVID Subgroup Analysis
Given the extensive time, effort and expense involved in perform-
ing large-scale clinical trials, there is a natural tendency to perform
subgroup analyses on the accumulated data subsequent to termi-
nation of the trial. Assmann et al. (1) recently stated: “Subgroup
analyses are particularly prone to overinterpretation, and one is
tempted to suggest “don’t do it” (or at least “don’t believe it”) for
many trials, but this suggestion is probably contrary to human
nature.” The report by Hallstrom et al. (2), a subgroup analysis of
the Antiarrhythmics Versus Implantable Defibrillators (AVID)
trial (3), falls into the category of “don’t believe it.”
The hypothesis of this substudy is reasonable—there may be
subgroups of AVID patients who do not benefit from an implant-
able defibrillator as opposed to amiodarone therapy. Based on their
data, the authors (2) conclude that the lowest-risk sextile is a
subgroup in which implantable defibrillators may not offer benefit.
However, this conclusion is faulty as the design of this substudy
forces the outcome to be negative.
The AVID trial (3) evaluated whether the strategy of antiar-
rhythmic drug therapy versus implantable defibrillator therapy is
better for treating patients with hemodynamically significant
ventricular tachycardia or ventricular fibrillation. In designing the
study, the investigators (4) concluded that a sample size of 1,200
patients was required to demonstrate the predicted benefit. The
trial was terminated early, after only 1,096 patients were enrolled,
because the analysis revealed that the difference in the primary
outcome variable had crossed the statistical boundary for early
termination. In the current report (3), the analysis of relative
benefit between antiarrhythmic drugs and the implantable defi-
brillator relies on a sample size that is one-sixth the total sample
size of the AVID trial. In addition to the small sample size, the
subgroup being investigated is the group of patients in which the
event rate and mortality is lowest. In subgroups with lower event
rates, the difference between event rates in the two treatment
groups typically decreases and a larger sample size is required to
demonstrate that the difference is significant. It is misleading to
suggest that one could demonstrate a difference in survival in the
lowest-risk sextile with the sample size that is available.
Study sample size is typically chosen so that the power of the
study or the probability of detecting the postulated difference is
high, typically in the 80% to 90% range. The calculated power of
this AVID substudy is 5.5% (calculated using a sample size of 166
patients, two year mortality of 11% [which was the observed
mortality], a 25% reduction in mortality to 8.25% by one of the
treatments), a value substantially less than the 80% to 90% value
used in designing a trial. This means that there was only a minimal
chance that this report could have demonstrated a difference
between the two therapies even if implantable defibrillators or
amiodarone reduced mortality by as much as 25%.
These substudy results should be interpreted as inadequate to
answer the question posed by the investigators. The data are
consistent with no benefit of implantable defibrillator over amio-
darone therapy, with a benefit of implantable defibrillator therapy
over amiodarone therapy and with a benefit of amiodarone therapy
over implantable defibrillator therapy. In contrast, the clinical
characteristics that identify the low risk sextile are interesting. A
suggestion that the cost-effectiveness in this low risk sextile may be
less favorable than in the other sextiles may also be valid. However,
only properly designed clinical trials will be able to address the
question of which therapy is appropriate or better in patients who
have a low arrhythmia risk. Until such studies are performed, one
can only conclude based upon the AVID trial that the strategy of
implantable defibrillator therapy has a survival benefit compared to
the strategy of antiarrhythmic drug therapy (amiodarone) in
patients who have suffered either ventricular fibrillation or hemo-
dynamically significant ventricular tachycardia.
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REPLY
We agree with Goldberger et al. that subgroup analyses are prone
to overinterpretation. One must be very cautious in dealing with
subgroup analyses, particularly when they are post hoc (ours was a
priori), based on essentially randomly defined subgroups (ours was
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based on a prespecified mechanistic “dose response” relationship),
and the result is based on lack of significance (if our null hypothesis
had been that there was no treatment effect in the lowest sextile,
not being able to reject the null would probably be a low-power
issue [Goldberger et al.’s power calculations are, in fact, based on
this null hypothesis]—however, our null hypothesis was that the
treatment effect would be the same in all sextiles, and we were able
to reject this null hypothesis with an, admittedly marginal, signif-
icance of 0.05).
Thus, while we would not disagree with Goldberger and
colleagues’ caution “don’t believe it,” we might also caution “don’t
disbelieve it.”
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Congenital Coronary Artery
Anomalies: Diagnosable, Premortem?
Dr. Pelliccia’s recent sage editorial comment on congenital coro-
nary artery anomalies (CCAA) (1) establishes an authoritative
impetus for the creation of an international registry of youths with
CCAA concomitant with a researched analysis of their clinical
profile and mode of noninvasive identification. The enormity of
this challenge is well appreciated on learning that in 20% of cases
wrong sinus coronary malformations are implicated as the cause of
catastrophic unexpected death in young people on the athletic
field.
Dr. Pelliccia’s summaries of the admirable presentation by Davis
et al. (2), and his citations of the literature review and conclusions
of Basso and colleagues (3), instill in the undersigned a warranted
enthusiasm and expectation for the noninvasive clinical and elec-
trocardiographic identification of wrong sinus coronary artery
anomalies, as has been accomplished for individuals with an
anomalous left coronary artery from the pulmonary trunk. Both
studies emphasize the importance of a history of exertional chest
pain or syncope as a marker of potential sudden death, alerting
physicians to the possibility of CCAA in the young athlete. In
their report, Basso et al. (3) determined that 37% of the compet-
itive athletes were symptomatic antemortem, and in their literature
review of patients with CCAA (among both athletes and nonath-
letes), Basso et al. found 94% of subjects were symptomatic, and,
most importantly, 72% complained of angina, syncope, or dyspnea,
on exertion. In this study cohort of young competitive athletes
dying suddenly, we are informed that a premortem electrocardio-
gram (ECG) was normal in all but two of nine patients; however,
the configurations of the ventricular ectopy demonstrated by the
two Italian professional athletes were unfortunately not clarified
(3). In their literature search of the 18 patients under 35 years of
age, Basso et al. showed that the ECG was reportedly abnormal in
50% of patients and the stress test positive in 22% (3).
In the four patients identified by Davis et al. (2), two possessed
abnormal electrocardiography, one demonstrating ventricular ec-
topy of right ventricular origin. Sudden death in these patients is
presumably due to ventricular tachyarrhythmia, consequent upon
vasospasm induced by endothelial injury, or an electrically unstable
myocardial cicatrix. The athlete with an anomalous origin of the
left coronary artery from the pulmonary trunk is much more readily
Figure 1. Anomalous origin of the left coronary artery from the pulmonary trunk. Q-waves and biphasic T-waves in the anterolateral leads I, aVL, V4, V5
and V6, suggestive of anterolateral injury in a 14-year-old male Caucasian. Negative U-waves are graphed and there is ST segment elevation in lead V4.
Kindness of Dr. Gary Webb, Director, Toronto Congenital Cardiac Centre for Adults, Toronto General Hospital.
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